IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GRONHOJ-LARSEN, et al.

Serial No.: 09/101,825

Filed: July 17, 1998

Art Unit: 1646

Washington, F.

June 29, 2001

For: SYNTHETIC IL-10 ANALOGUES) Docket No.: GRONHOJ-LARSEN=2

INFORMAL COMMUNICATION

HAND CARRY TO EXAMINER

Commissioner of Patents Washington, D.C. 20231

Sir:

The Examiner has maintained the enablement (pp. 3-9) and written description (pp. 10-11) rejections. All other rejections have been withdrawn. Claim 32 is merely objected to.

The Examiner concedes enablement only for

- (1) "peptides having SEQ ID NOs:1 and 19-22...wherein the amino acid substitutions are limited to the naturally occurring amino acids", and
- (2) treatment (<u>not</u> prevention) of pancreatitis (but not other diseases)

Applicants would be willing to impose a maximum peptide length, per page 22, lines 21-25.

Applicants would also be willing to limit the non-genetically encoded AAs to those set forth at page 17, line 31 to page 19, line 2.

Three catalogues providing such AAs are cited in the specification; copies are enclosed herewith.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant

Iver P. Cooper

Reg. No. 28,005

624 Ninth Street, N.W. Washington, D.C. 20001 Telephone: (202) 628-5197 Facsimile: (202) 737-3528

IPC:lms

F:\,P\Plou\GronhojLarsen2\INFORMALCOMM.WPD